WHO announces the expanded scope of the WHO Director-General’s Flagship Initiative on TB over the period 2023-2027 to support fast-tracking progress towards ending TB and achieving Universal Health Coverage by 2030.

Tuberculosis (TB) is an airborne global pandemic that kills 1.6 million people each year, causes over 10 million people to fall sick, and poses catastrophic costs for patients and rising costs for health systems. The growing threat of drug-resistant TB is a major contributor to the global burden of antimicrobial resistance (AMR) and a significant cause of AMR deaths. New vaccines are urgently needed to tackle this crisis. Yet, despite the huge threat posed by drug-resistant TB, political and financial support falls dangerously short of what is needed to effectively address this threat.

The Fast Track the Cure campaign demands universal access to six-month drug-resistant TB cure by 2024.

Treatment Action Group and the 1/4/6x24 Campaign Coalition launch the 1/4/6x24 World TB Day Toolkit to support advocacy the week of World TB Day for access to shorter, safer regimens for TB prevention and treatment.

The Coordination Hub launches the World TB Day Advocacy Toolkit to support the kick-start of advocacy at the national level in the lead up to the 2023 UN High-Level Meeting on TB.

In the lead up to World TB Day, Dr Tereza Kasaeva, Director and Ms Hannah Monica Dias, Cross-Cutting Lead, of the WHO's Global TB Program along with Prof Madhukar Pai, Associate Director of McGill International TB Centre and Canada Research Chair in Epidemiology & Global Health, co authored a commentary in The Lancet on fast-tracking progress to End TB, emphasizing high-level opportunities for investment and action.

The World Health Organization launches the World TB Day Advocacy & Communications Toolkit, featuring key messages and calls to action, as well as promotional posters, tiles and infographics.

The Toolkit will help raise awareness for the upcoming World TB Day and can be used, adapted, or tailored to fit everyone's needs and vision.

TAG applauds Molbio’s agreement with the Stop TB Partnership, USAID, and the Global Fund to reduce the price of Truenat diagnostics for TB from US$9 per test to $7.90 per test and to provide quality service and maintenance of Truenat testing instruments globally.

RESIST-TB released its March 2023 newsletter with the latest updates and research publications on drug-resistant TB.